[go: up one dir, main page]

MA33219B1 - Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation - Google Patents

Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation

Info

Publication number
MA33219B1
MA33219B1 MA34280A MA34280A MA33219B1 MA 33219 B1 MA33219 B1 MA 33219B1 MA 34280 A MA34280 A MA 34280A MA 34280 A MA34280 A MA 34280A MA 33219 B1 MA33219 B1 MA 33219B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
methods
receptor
substituted azoanthracene
azoanthracene derivatives
Prior art date
Application number
MA34280A
Other languages
Arabic (ar)
English (en)
Inventor
Adnan M M Mjalli
Christopher Behme
Daniel P Christen
Dharma Rao Polisetti
James Quada
Kalpathy Santhosh
Muralidhar Bondlela
Mustafa Guzel
Ravindra Reddy Yarragunta
Devi Reddy Gohimukkula
Robert Carl Andrews
Stephen Thomas Davis
Thomas Scott Yokum
Jennifer L R Freeman
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of MA33219B1 publication Critical patent/MA33219B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Secondary Cells (AREA)

Abstract

La présente invention porte sur des dérivés d'azoanthracène substitués ou sur leurs sels pharmaceutiquement acceptables, qui modulent le récepteur au GLP-1 humain et qui peuvent être utiles dans le traitement de maladies, troubles ou états dans lesquels une modulation du récepteur au GLP-1 humain est utile, tels que le diabète sucré de type 2. L'invention porte également sur des compositions pharmaceutiques comprenant ces composés et sur l'utilisation de ces composés et de ces compositions dans le traitement de telles maladies, troubles ou états dans lesquels la modulation du récepteur au GLP-1 humain est utile.
MA34280A 2009-03-30 2010-03-30 Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation MA33219B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (fr) 2009-03-30 2010-03-30 Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA33219B1 true MA33219B1 (fr) 2012-04-02

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34280A MA33219B1 (fr) 2009-03-30 2010-03-30 Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation

Country Status (18)

Country Link
US (3) US8383644B2 (fr)
EP (1) EP2413693B1 (fr)
JP (1) JP5755217B2 (fr)
KR (1) KR101732978B1 (fr)
CN (1) CN102378574B (fr)
AU (1) AU2010232750B2 (fr)
BR (1) BRPI1013579A2 (fr)
CA (1) CA2757084C (fr)
DK (1) DK2413693T3 (fr)
EA (1) EA023430B1 (fr)
ES (1) ES2553645T3 (fr)
HK (1) HK1164050A1 (fr)
IL (1) IL214822A (fr)
MA (1) MA33219B1 (fr)
MX (1) MX2011010347A (fr)
SG (1) SG174205A1 (fr)
TN (1) TN2011000437A1 (fr)
WO (1) WO2010114824A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2413693T3 (en) 2009-03-30 2015-11-16 Vtv Therapeutics Llc Substituted azoanthracenderivater, pharmaceutical compositions and methods for use thereof
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
EP2768799B1 (fr) 2011-10-17 2019-08-07 Biotheryx Inc. Biaryle alkyle amides substitués
JP6445459B2 (ja) * 2013-01-17 2018-12-26 ブイティーブイ・セラピューティクス・エルエルシー Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用
CN107072970B (zh) 2014-08-29 2021-05-25 得克萨斯州大学系统董事会 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
SG11202007966UA (en) * 2018-05-08 2020-11-27 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
CA3045644C (fr) * 2018-06-13 2024-01-16 Pfizer Inc. Antagonistes du recepteur glp-1 et leurs utilisations
US20230174546A1 (en) 2020-04-01 2023-06-08 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of glp-1 receptor agonist and preparation method therefor
US20230174547A1 (en) * 2020-04-01 2023-06-08 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of glp1 receptor agonist, and preparation method therefor
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021242806A1 (fr) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Intermédiaires et procédés de préparation d'un agoniste du récepteur glp-1
CN115667222B (zh) * 2020-05-28 2023-09-29 杭州中美华东制药有限公司 一种制备glp-1受体激动剂的方法
WO2021242807A1 (fr) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Procédés de préparation de méthyl(s)-2-amino-3-(4-(2,3-diméthylpyridin-4-yl)phényl)propionate et de sels d'acide chlorhydrique associés
TW202210461A (zh) 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種（ｓ）—２—胺基—３—（４—（２，３—二甲基吡啶—４—基）苯基）丙酸甲酯二酸鹽的製備方法
EP4163271A4 (fr) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Procédé de préparation de méthyl (s)-2-amino-3-(4-(2,3-diméthylpyridin-4-yl)phénylpropionate et son sel
US20230348484A1 (en) 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist free base
WO2022007979A1 (fr) 2020-09-01 2022-01-13 江苏恒瑞医药股份有限公司 Dérivé d'imidazole condensé, son procédé de préparation et son utilisation médicale
WO2022061091A1 (fr) * 2020-09-21 2022-03-24 Vtv Therapeutics Llc Forme amorphe de dérivé d'isoquinoléine
CA3194283A1 (fr) * 2020-10-08 2022-04-14 Eli Lilly And Company Composes de 6-methoxy-3,4-dihydro-1h-isoquinoline utiles dans le traitement du diabete
WO2022078152A1 (fr) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation
MX2023006186A (es) 2020-11-27 2023-08-07 Shenzhen Salubris Pharm Co Ltd Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
WO2022199458A1 (fr) 2021-03-22 2022-09-29 杭州中美华东制药有限公司 Agoniste du récepteur de glp-1 de type thiophène et son utilisation
EP4317145A1 (fr) 2021-03-24 2024-02-07 Shionogi & Co., Ltd Composition pharmaceutique contenant un agoniste du récepteur glp-1 comportant un cycle fusionné
WO2022262143A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Procédé de préparation de borate de pyridine
CN117500808A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
WO2022268152A1 (fr) 2021-06-24 2022-12-29 杭州中美华东制药有限公司 Agoniste de récepteurs de glp-1 et composition et utilisation associées
WO2023029979A1 (fr) * 2021-09-03 2023-03-09 杭州中美华东制药有限公司 Procédé de préparation d'un intermédiaire agoniste du récepteur de glp-1
WO2023038039A1 (fr) 2021-09-08 2023-03-16 塩野義製薬株式会社 Médicament destiné à la prévention et au traitement de maladies liées à l'activité anti-obésité
WO2023051490A1 (fr) 2021-09-28 2023-04-06 杭州中美华东制药有限公司 Composition solide d'agoniste du récepteur glp-1
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (fr) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. Dérivés de 1,4-benzoxazine, leur préparation et leur application
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
EP1147094A1 (fr) * 1999-01-15 2001-10-24 Novo Nordisk A/S Agonistes non peptidiques de glp-1
CA2441790A1 (fr) * 2001-03-27 2002-10-03 Actelion Pharmaceuticals Ltd. Derives de 1,2,3,4-tetrahydro-isoquinoline en tant qu'antagonistes du recepteur de l'urotensine ii
US6933303B2 (en) * 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
BRPI0408681A (pt) * 2003-03-26 2006-03-28 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2008118935A1 (fr) * 2007-03-26 2008-10-02 Neurogen Corporation Composés et procédés de préparation d'aminométhyl-2,3,8,9-tétrahydro-7h-1,4-dioxino[2,3-e]indol-8-ones substitués
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
WO2009126709A1 (fr) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands pour le récepteur de glp-1 et procédés de découverte de ceux-ci
DK2413693T3 (en) 2009-03-30 2015-11-16 Vtv Therapeutics Llc Substituted azoanthracenderivater, pharmaceutical compositions and methods for use thereof
US8501982B2 (en) 2010-06-09 2013-08-06 Receptos, Inc. GLP-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
EA201171197A8 (ru) 2014-10-30
US20130096150A1 (en) 2013-04-18
JP2012522060A (ja) 2012-09-20
MX2011010347A (es) 2011-11-29
AU2010232750A1 (en) 2011-09-08
EP2413693A1 (fr) 2012-02-08
CN102378574B (zh) 2013-11-20
CN102378574A (zh) 2012-03-14
WO2010114824A1 (fr) 2010-10-07
EA201171197A1 (ru) 2012-04-30
US20110160198A1 (en) 2011-06-30
US20150148539A1 (en) 2015-05-28
JP5755217B2 (ja) 2015-07-29
US9175003B2 (en) 2015-11-03
SG174205A1 (en) 2011-10-28
HK1164050A1 (en) 2012-09-21
DK2413693T3 (en) 2015-11-16
EP2413693A4 (fr) 2012-08-22
KR20120006506A (ko) 2012-01-18
US8383644B2 (en) 2013-02-26
US8987295B2 (en) 2015-03-24
IL214822A (en) 2016-08-31
EP2413693B1 (fr) 2015-09-09
WO2010114824A8 (fr) 2011-10-06
IL214822A0 (en) 2011-11-30
CA2757084C (fr) 2017-08-29
CA2757084A1 (fr) 2010-10-07
EA023430B1 (ru) 2016-06-30
BRPI1013579A2 (pt) 2020-11-03
KR101732978B1 (ko) 2017-05-08
ES2553645T3 (es) 2015-12-10
AU2010232750B2 (en) 2015-10-29
TN2011000437A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
MA34474B1 (fr) Agonistes de gpr40
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
MA29909B1 (fr) Derives de pyridazine
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
MA31352B1 (fr) Dérivés imidazolidine carboxamide comme modulateurs de p2x7.
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA38648B1 (fr) Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases
MA29723B1 (fr) Composes
MA29775B1 (fr) Derives de pyrazolone